previous arrow
next arrow

Omaveloxolone & Friedreich's Ataxia

How might Omaveloxolone Treat Friedreich's ataxia?

A hallmark of Friedreich's ataxia (FA) is impairment of antioxidative defense mechanisms. Oxidative stress experienced by the body causes damage to cells and is thought to play a role in FA disease progression. Studies demonstrate that Nrf2 (nuclear factor erythroid-derived 2-related factor) signaling is impaired in people with FA. Omaveloxolone is an investigational drug that activates Nrf2, and this leads to the induction of antioxidant target genes, which can protect cells from damage caused by oxidative stress. This may be of therapeutic benefit to people with FA.